

Appendix 4—Measures of association between First Nation status (reference general population) and each of the study outcomes, matched cohort#2 (Rezaie and colleagues' case definition)

Outcomes	Stratified analysis					
	Full-group analysis (n=990)		Crohn's Disease (n=526)		Ulcerative Colitis (n=464)	
	Unadjusted HR (95%CI)	Adjusted HR (95%CI)*	Unadjusted HR (95%CI)	Adjusted HR (95%CI)**	Unadjusted HR (95%CI)	Adjusted HR (95%CI)***
Outpatient gastroenterologist visit	0.86 (0.70-1.05)	0.87 (0.71-1.06)	0.80 (0.58-1.10)	0.81 (0.59-1.11)	0.90 (0.70-1.17)	0.91 (0.70-1.18)
Colonoscopy	0.96 (0.79-1.18)	0.90 (0.73-1.10)	0.82 (0.58-1.15)	0.81 (0.58-1.15)	0.95 (0.73-1.22)	0.95 (0.74-1.23)
Prescription claim for IBD	0.74 (0.61-0.90)	0.68 (0.56-0.83)	0.61 (0.44-0.86)	0.61 (0.43-0.85)	0.74 (0.58-0.95)	0.74 (0.57-0.95)
Prescription claim of a Biologic	0.66 (0.42-1.05)	0.74 (0.46-1.17)	0.77 (0.43-1.39)	0.78 (0.43-1.41)	0.67 (0.32-1.41)	0.67 (0.32-1.42)
Prescription claim of an IM	0.66 (0.44-0.93)	0.74 (0.52-1.05)	0.63 (0.39-1.04)	0.65 (0.40-1.07)	0.82 (0.50-1.36)	0.85 (0.51-1.42)
Prescription claim of a 5-ASA	0.86 (0.70-1.06)	0.74 (0.60-0.91)	0.66 (0.45-0.97)	0.63 (0.43-0.92)	0.80 (0.62-1.03)	0.79 (0.62-1.02)
IBD-specific hospitalization	1.21 (0.93-1.56)	1.28 (0.99-1.67)	1.28 (0.88-1.86)	1.31 (0.90-1.91)	1.25 (0.87-1.80)	1.25 (0.87-1.80)
IBD-related hospitalization	1.33 (1.04-1.68)	1.39 (1.09-1.77)	1.29 (0.90-1.84)	1.28 (0.89-1.83)	1.48 (1.06-2.06)	1.47 (1.06-2.05)
Surgery for IBD	1.06 (0.76-1.48)	1.04 (0.74-1.46)	0.83 (0.48-1.43)	0.82 (0.47-1.43)	1.26 (0.82-1.94)	1.23 (0.80-1.89)

HR: hazard ratio, 95%CI: 95% confidence interval. Bold values denote statistically significant results.

* Models adjusted by rural or urban status, and diagnostic type (n=986).

** Crohn's Disease group, models adjusted by rural or urban status (n=524).

*** Ulcerative colitis group, models adjusted by rural or urban status (n=462).

Appendix 4, as supplied by the authors. Appendix to: Marques Santos JD, Fowler S, Jennings D, et al. Health care utilization differences between First Nations people and the general population with inflammatory bowel disease: a retrospective cohort study from Saskatchewan, Canada. CMAJ Open 2022. doi:10.9778/cmajo.20220118. Copyright © 2022 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.